TriSalus Life Sciences (TLSI) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TriSalus Life Sciences (TLSI) has outperformed TransMedics Group (TMDX) over the past year, losing 14.8% versus a loss of 33.1%. Over five years, TMDX leads with a +197.6% price change compared with -58.3% for TLSI. TransMedics Group is the larger company by market cap ($2.74 billion vs $254.3 million), about 10.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TLSI | TMDX |
|---|---|---|
| Share price | $4.13 | $79.00 |
| Market cap | $254.30M | $2.74B |
| 1-day change | -2.82% | -2.55% |
| YTD return | -40.83% | -35.06% |
| 1-year return | -14.85% | -33.08% |
| 5-year return | -58.28% | +197.55% |
| P/E ratio (TTM) | — | 20.47 |
| Forward P/E | — | 35.05 |
| EPS (TTM) | $-1.22 | $3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $605.49M |
| Revenue growth (YoY) | — | +37.13% |
| Net income (latest FY) | — | $190.29M |
| Gross margin | — | 59.92% |
| Operating margin | — | 17.93% |
| Net margin | — | 31.43% |
| 52-week high | $7.95 | $156.00 |
| 52-week low | $2.20 | $60.11 |
| Distance from 52-week high | -48.05% | -49.36% |
| Analyst consensus | none | buy |
| Avg. price target upside | +151.82% | +26.35% |
| Average volume | 275.38K | 820.41K |
| Shares outstanding | 61.57M | 34.68M |
| Employees | 102 | 898 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TransMedics Group is about 10.8 times larger than TriSalus Life Sciences by market value ($2.74B vs $254.30M).
- TLSI has outperformed TMDX by 18.2 percentage points over the past year.
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 898 employees
TLSI vs TMDX FAQ
Which is bigger, TriSalus Life Sciences or TransMedics Group?
TransMedics Group (TMDX) is larger, with a market capitalization of $2.74B compared with $254.30M for TriSalus Life Sciences (TLSI).
Which stock has performed better over the past year, TLSI or TMDX?
TLSI returned -14.85% over the past 12 months, compared with -33.08% for TMDX (price return, excluding dividends). Past performance does not predict future results.
Are TriSalus Life Sciences and TransMedics Group in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for TriSalus Life Sciences and Biotechnology: Electromedical & Electrotherapeutic Apparatus for TransMedics Group.